Bio Break: Clinical Trials for Medical Devices vs. Pharmaceuticals
In this episode of Bio Break, Joris van der Heijden and Nick Allan break down the key differences and similarities between clinical trials for medical devices and pharmaceutical products. As the conversation unfolds, they provide valuable insights into the distinct processes and challenges associated with these two types of trials, including the complexities of combination devices that bridge both worlds.
Nick begins by explaining the unique goals of clinical trials for medical devices. These trials focus on proving safety, efficacy, and the performance claims of the device in real-world settings. For example, diagnostic devices must demonstrate their ability to detect targets reliably and accurately, whether in a clinical laboratory or at the point of care.
In contrast, Nick outlines the four distinct phases of pharmaceutical clinical trials:
- Phase 1: Conducted with healthy volunteers to evaluate safety and dosage, often involving a small group of participants (around 50 people).
- Phase 2: Tests the drug’s efficacy in the target patient population, expanding the study to hundreds of participants.
- Phase 3: Compares the drug against existing treatments or the standard of care in a much larger population, often with thousands of participants, to prove differentiation and effectiveness.
- Phase 4: Post-market surveillance monitors long-term safety, side effects, and real-world performance after regulatory approval.
Nick highlights how medical device trials share parallels with pharmaceutical trials but often focus on different priorities, such as functional testing, usability, and regulatory claims. The discussion becomes especially intriguing when considering combination products, which integrate medical devices with pharmaceutical components, requiring alignment across both regulatory pathways and clinical trial objectives.
This episode is essential viewing for anyone working in medical device development, pharmaceuticals, or combination products. Gain a clear understanding of the clinical trial landscape and how these processes ensure safety, efficacy, and market readiness for innovative healthcare solutions.
Clinical Trials for Medical Devices vs. Pharmaceuticals
Related Resources
We all know medical devices have labels, but how often do we consider their purpose and the effort required to ensure they provide the right information? Device labelling serves as the interface between the manufacturer, the user, and regulatory bodies. (Note that being from Canada, we spell labelling with two Ls.)
Sterilization is a critical process in the medical device industry as it provides a reliable way to ensure that devices are free from harmful microorganisms when they are used on patients. This blog talks about the categories of sterilization currently used on medical devices in manufacturing settings. It also addresses concerns surrounding the use of ethylene oxide (EtO), an indispensable method for sterilizing heat and moisture sensitive devices.
Predicting the trends of a new year is always interesting and a bit unpredictable. We asked our medical device design and development professionals to submit their most interesting medtech trends for 2025 and the reasoning behind their prediction. The results were surprisingly focused on two major trends: Home Healthcare and Wearable Devices. Within these categories, several technologies were identified including edge computing, IoT, and connected devices. In no particular ranking, here are our 2025 predictions:
The U.S. Food and Drug Administration (FDA) and the Office for Human Research Protections (OHRP) have released a draft guidance document, Considerations for Including Tissue Biopsies in Clinical Trials, issued in January 2025. It provides recommendations for sponsors, investigators, institutions, and Institutional Review Boards (IRBs) on the safe and ethical incorporation of tissue biopsies in clinical trials.